ARALEN HYDROCHLORIDE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARALEN HYDROCHLORIDE is a legacy small-molecule injectable approved in 1949, likely indicated for malaria and autoimmune conditions based on historical chloroquine formulations. The exact mechanism of action and indication portfolio are not currently documented in available data. This is a Sanofi-sponsored product with established clinical use across multiple decades.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling potential team restructuring and shift from growth to retention-focused roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ARALEN HYDROCHLORIDE offers stability in a mature, low-innovation product with minimal current hiring; career growth is constrained. This role suits professionals seeking steady-state brand stewardship or transition preparation into generic/value-based care models.
Brand ManagerMedical Science Liaison
Worked on ARALEN HYDROCHLORIDE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.